WSJ’s MarketWatch interviews the CEO of Clinical Data, Drew Fromkin. They talk about his ideas on biomarkers, GINA, personalized medicine, and what it means for consumers whose confidence in genetic testing, and the insurance coverage they may or may not get, is just starting to improve.